Multiple effects of amprenavir against Candida albicans

FEMS Yeast Res. 2010 Mar;10(2):221-4. doi: 10.1111/j.1567-1364.2009.00595.x. Epub 2009 Nov 23.

Abstract

Secreted aspartyl peptidases (Saps) are virulence attributes produced by Candida albicans that participate in multiple aspects of the fungal biology and pathogenesis. In the present paper, we have shown that amprenavir, a peptidase inhibitor used in HIV chemotherapy, inhibited Sap2 and growth of C. albicans and also promoted ultrastructural alterations. Esterase activity, sterol content, biofilm formation and the expression of surface mannose- and sialic acid-rich glycoconjugates were also reduced by amprenavir.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspartic Acid Endopeptidases / antagonists & inhibitors*
  • Biofilms / drug effects
  • Blood / microbiology
  • Candida albicans / drug effects*
  • Candida albicans / growth & development
  • Candida albicans / metabolism
  • Candida albicans / ultrastructure
  • Candidiasis / microbiology
  • Carbamates / pharmacology*
  • Culture Media
  • Fungal Proteins / antagonists & inhibitors*
  • Fungemia / microbiology
  • Furans
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Sulfonamides / pharmacology*

Substances

  • Carbamates
  • Culture Media
  • Fungal Proteins
  • Furans
  • HIV Protease Inhibitors
  • Sulfonamides
  • amprenavir
  • Aspartic Acid Endopeptidases
  • SAP2 protein, Candida